DETERMINATION OF THE ANTIMETABOLITE GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE) AND OF 2',2'-DIFLUORO-2'-DEOXYURIDINE BY F-19 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY
DETERMINATION OF THE ANTIMETABOLITE GEMCITABINE (2',2'-DIFLUORO-2'-DEOXYCYTIDINE) AND OF 2',2'-DIFLUORO-2'-DEOXYURIDINE BY F-19 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY
复制标题
DOI：
10.1006/abio.1993.1451
复制
发表时间：
1993-10-01
影响因子：
2.9
通讯作者：
VERMORKEN, JB
中科院分区：
文献类型：
--
作者：
EDZES, HT;PETERS, GJ;VERMORKEN, JB
The analysis of the new antimetabolite 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine, Eli Lilly Corp.) and of its metabolic deamination product, 2′,2′-difluoro-2′-deoxyuridine, in urine and plasma by means of19F NMR is described. Both compounds show AB-type NMR spectra which are characterized as a function of pH at a magnetic field strength of 9.4 T. In the physiological pH range the spectra of both compounds are distinct, despite the fact that both compounds have almost identical average19F shifts. A linear relation between NMR intensity and concentration in urine has been established. The NMR method does not require sample pretreatment and allows for rapid, nondestructive analysis of Gemcitabine concentrations over 0.01 mM. Separation of the two compounds in vivo by19F NMR spectroscopy is difficult to achieve.
